Many compounds used for the treatment of malignant tumors are cytotoxic drugs that can induce tumor cell death by apoptosis (1) . The specific intracellular damage induced by these drugs is generally well characterized. For example, cisplatin, one of the most widely used anticancer drugs, reacts with the target genomic DNA to form DNA adducts (2) . This DNA damage can induce cell cycle arrest (3) and apoptosis (4, 5) . However, the mechanisms by which the specific damage induced by the chemotherapeutic agents are converted into a death signal remain poorly understood.
A key regulator of apoptosis is the Fas receptor/Fas ligand (Fas/FasL) system, which was recently found to be involved in leukemia cell death induced by two cytotoxic drugs, namely, doxorubicin and methotrexate (6) . The type I transmembrane receptor Fas, a molecule belonging to the tumor necrosis factor/nerve growth factor receptor family (7) , is also an important mediator of immunologically relevant target cell apoptosis (8) . This receptor is constitutively expressed on the basolateral membrane of normal colon epithelium (9) and the plasma membrane of a variety of cancer cell lines (10) . Fas-mediated apoptosis can be triggered following engagement of the target cell Fas receptor by its specific cognate ligand (i.e., FasL) and by the prototypic agonistic anti-Fas monoclonal antibodies CH11 and APO-1 (11, 12) . FasL is expressed by T cells upon activation with phorbol myristate acetate and ionomycin (13) as well as by freshly isolated and Fc receptor-activated natural killer cells (14, 15) . In combination with the granule exocytosis mechanism, FasL was involved in the immune clearance of Fas-expressing target cells (16) . FasL expression is not restricted to lymphoid cells and is also observed on certain epithelial cells, Sertoli cells, and neurons (17) (18) (19) (20) . Moreover, several tumor cell types were recently shown to express functional FasL. Since activated T cells are inherently sensitive to Fas-mediated killing, the expression of FasL on tumor cells was suggested to account for their immune escape (21, 22) . Thus, the Fas/FasL system could either contribute to immune cell-mediated and anticancer drug-induced tumor cell death or protect the tumor cells from immune clearance by triggering immune cell death.
In the present study, we further analyze the relationship between chemotherapeutic drugs and the Fas/FasL system in human tumor cell lines.
Materials and Methods
Cell culture, treatment, and flow cytometry analyses. The human HT29, HCT116, and HCT8R colon carcinoma cell lines and the U937 and human Jurkat leukemia cell lines were obtained from the American Type Culture Collection (Rockville, MD) and maintained in Eagle minimum essential medium and RPMI-1640 medium, respectively. These media were complemented with 10% fetal bovine serum and 2 mM L-glutamine (Biowhittaker Co., Fontenay sous Bois, France). Cells (2 × 10 6 ) were cultured in 75-cm 2 flasks for 2 days before treatment with 10 M cisplatin (Roger Bellon Chemical Co., Neuilly, France), 10 M doxorubicin (Roger Bellon Chemical Co.), 3 M mitomycin C (Choay Laboratories, Paris, France), 260 M fluorouracil (Roche Chemical Co., Neuilly), 0.3 M camptothecin (Sigma Chemical Co., St. Quentin Fallavier, France), or 200 IU/mL interferon ␥ (IFN ␥) (Roussel Uclaf Chemical Co., Romainville, France) for 4 and 24 hours. Fas expression was measured by flow cytometry 24 or 48 hours after the start of the treatment on trypsinized cells that had been incubated for 45 minutes at 4°C with the mouse anti-human Fas clone DX2 (Pharmingen Co., San Diego, CA) or a mouse isotype-matched control DAK-GO (Dako Co., Trappes, France), both of which were diluted 1:800 in phosphatebuffered saline containing 0.5% bovine serum albumin and 0.1% sodium azide (Sigma Chemical Co.). After two washes in phosphate-buffered saline, cells were incubated for 45 minutes with a fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin G (IgG) (Amersham Co., Les Ulis, France) and analyzed on a flow cytometer (Becton Dickinson Co., Le Pont de Claix, France). Quantification of Fas expression was performed with the QIFIKIT assay (Dako Co.); this assay provides a well-defined quantity of mouse IgG-containing beads that were reacted with the secondary antibody in saturating amounts, allowing extrapolation of antigen-binding capacity from the standardization curve. Peripheral blood leukocytes (PBLs) were reacted on ice with biotinylated antihuman FasL clone NOK-1 (Pharmingen Co.), and a streptavidin-phycoerythrin complex (Caltag Laboratories, San Francisco, CA) was used for the secondary labeling.
Fas gene transcription analyses. For northern blot assays, total RNA was prepared by use of the Bioprobe RNA lysis kit (Bioprobe System Co., Montreuil, France). RNA was separated on a 1% agarose-denaturing gel containing 2. P-labeled RNA samples were hybridized with 10 g of linearized target plasmids containing the full-length complementary DNA of Fas and GAPDH. RNA stability assays were performed by incubating the cells in the presence or absence of 5 g/mL dactinomycin (Sigma Chemical Co.) for 3-6 hours. Total RNAs were transferred to Hybond-C extra nitrocellulose membranes and autoradiographed for 4 days at −80°C, and autoradiographic band intensities were quantified with the use of a gel analyzer (Biocom Co., Les Ulis).
Murine FasL production and cytotoxic assays. Murine FasL was collected from FasL-transfected murine Neuro2A cell supernatants (Dr. A. Fontana, Zurich University Hospital, Switzerland) after 2 days of culture in Dulbecco's modified Eagle medium (Biowhittaker Co.) containing 1% fetal bovine serum. Soluble FasL toxicity specificity on various cell lines was reported previously (23). This supernatant was concentrated 100-fold by use of the ultrafree-15 centrifugal filter device Biomax-10K Membrane (Millipore Co., Molsheim, France). Control supernatant from mock-transfected cells obtained under the same conditions did not induce any cytotoxicity or proliferation of HT29 cells (data not shown). One arbitrary unit of FasL or mock supernatant was defined as 1 L of a 100-fold concentrated supernatant of Neuro2A cells that had been confluent for 48 hours. A unique pool of FasL or mock supernatant was used throughout this study. HT29 cells (10 4 ) were seeded in 96-well flat-bottomed plates for 2 days before treatment with either 10 M cisplatin or 200 IU/mL IFN ␥. Twenty-four hours after the start of the treatment, cells were exposed for another 72 hours to the indicated concentrations of either agonistic CH11 antiFas monoclonal antibody (Biovalley Co., Rockville, MD), TEPC183 isotypematched control antibody (Sigma Chemical Co.), or a concentrated supernatant of FasL-transfected Neuro2A cells. The control antibody had been dialyzed in phosphate-buffered saline by use of the Slide-A-Lyzer cassette (Pierce Chemical Co., Asnières, France) in order to remove sodium azide. When indicated, antagonistic anti-Fas blocking antibody clone ZB4 (Biovalley Co.) was added 1 hour before incubation with antibodies or FasL. Surviving cells were measured by methylene blue staining (24) . The percentage of viability was calculated by the following formula: 100 × (optical density values of monoclonal antibodytreated cells/optical density values of cells not treated with monoclonal antibody). Soluble FasL activity was detected by measuring the cytotoxic activity of cell culture supernatants on Fas-expressing Jurkat cells (5 × 10 4 cells per well) as previously described (25) .
Cytotoxic activity of PBLs. PBLs from healthy donors were isolated by use of Lymphoprep (Biovalley Co.). Target cells (2.5 × 10 6 ) were labeled for 19 hours in the presence of 0.2 mCi Na 2
51
CrO 4 (NEN, Dupont de Nemours Chemical Co., Les Ulis) and trypsinized. Then 10 4 target cells were seeded in quadruplicate in 96-well plates, preincubated or not preincubated with 2 g/mL ZB4 antibody for 1 hour, and incubated with freshly isolated PBLs at the indicated effector-to-target ratio for 16 hours. 51 Cr release was measured in a liquid gamma counter, and the cytotoxicity was calculated by the following formula: cytotoxicity (%) ‫ס‬ 100 × [(experimental release − spontaneous release)/(maximum release − spontaneous release)].
Reverse transcription-polymerase chain reaction analysis of FasL expression in PBLs. Single-stranded complementary DNA was prepared from 1 g total RNA in a 30-L reaction mixture containing 100 pmol oligo(dT) 18 , 200 U Moloney murine leukemia virus reverse transcriptase (Gibco BRL Co., Cergy Pontoise, France), and 1 mM deoxynucleoside triphosphate (dNTP) (Laboratories Eurobio, Les Ulis). A reverse transcription reaction mixture (10 L) was diluted with 40 L polymerase chain reaction buffer containing 1.5 mM MgCl 2 , 50 pmol forward and reverse oligonucleotides, and 0.25 mM dNTP. Two polymerase chain reactions were set up, corresponding to FasL (forward: 5Ј-CTGGGGATGTTTCAGCTCCTTC-3Ј; reverse: 5Ј-CTTCACTCCAGAAAG-CAGGAC-3Ј) and ␤ 2 -microglobulin (forward: 5Ј-AAGTGGAGCATTCAGAC-TTGTC-3Ј; reverse: 5Ј-CTTACATGTCTCGATCCCACTT-3Ј). Reverse transcription-polymerase chain reaction products isolated on a 1% agarose gel were transferred to Hybond-C extra nitrocellulose membranes and hybridized with full-length [ 32 P]Fas ligand complementary DNA (Dr. S. Nagata, Osaka Bioscience Institute).
Statistics. Quantitative experiments were analyzed by use of Student's t test. All P values resulted from the use of two-sided tests.
Results
The effect of cisplatin and other anticancer drugs on Fas receptor expression on the surface of tumor cells was analyzed by quantitative flow cytometry experiments in the human colon carcinoma cell line HT29. Since IFN ␥ was reported to enhance Fas receptor expression on HT29 cells (11), IFN ␥-treated HT29 cells were used as a positive control. Fas receptor expression at the cell surface was increased 2.5-fold and sixfold when studied 24 and 48 hours, respectively, after a 24-hour exposure to 200 IU/mL IFN ␥. Exposure of HT29 cells to a clinically relevant concentration of cisplatin (10 M) for 4 hours induced a 2.5-fold and a fourfold increase in Fas expression when studied 24 and 48 hours, respectively, after the start of cell treatment ( Figs. 1 and  2 ). The increase in Fas receptor was not specific to cisplatin, since a similar threefold to fivefold increase was observed in HT29 cells after a 4-hour exposure to doxorubicin (10 M), mitomycin C (3 M), fluorouracil (260 M), or camptothecin (0.3 M), 24 and 48 hours after the start of cell treatment (Fig.  1 ). For all drugs tested, the concentrations used were those that caused 50% inhibition of growth (i.e., the IC 50 value) as measured on HT29 cells (24) . Furthermore, the increase in Fas receptor was not specific for the HT29 cell line, since a similar increase in Fas receptor expression was observed in two other human colon carcinoma cell lines, HCT8R and HCT116, as well as in the human U937 leukemia cell line after a similar exposure to cisplatin (data not shown).
Enhanced expression of the Fas receptor was related to a twofold increase in the Fas messenger RNA level in cisplatintreated HT29 cells (Fig. 3, A) . In vitro nuclear run-on experiments demonstrated that the Fas messenger RNA increase was partly due to an enhanced transcription of the gene (Fig. 3, B) . To determine whether Fas messenger RNA turnover could also be affected by cell treatment with cisplatin, the transcriptional activity of HT29 cells was suspended by addition of 5 g/mL dactinomycin to the cultures 24 hours after the start of cisplatin treatment. The Fas messenger RNA half-life was about 3 hours in untreated HT29 cells and was increased to more than 6 hours in HT29 cells treated with cisplatin (Fig. 4) . In IFN ␥-treated cells, the Fas messenger RNA increase (Fig. 3, A) was also related to both enhanced transcription rate (Fig. 3, B) and increased messenger RNA half-life (Fig. 4) .
To determine whether enhanced Fas receptor expression induced in HT29 cells by cisplatin exposure was associated with an increased sensitivity of the cells to Fas-mediated cytotoxicity, we performed two series of experiments. First, HT29 cells were exposed to various concentrations of the agonistic CH11 antiFas monoclonal antibody for 72 hours. In accordance with recently published results (21), the CH11 antibody was poorly cytotoxic against untreated HT29 cells at concentrations up to 100 ng/mL (Fig. 5, A) . Its cytotoxic activity was greatly enhanced after a 4-hour treatment with cisplatin (Fig. 5, B) or a 24-hour treatment with IFN ␥ (Fig. 5, C) . Second, because the physiologic effector of Fas-mediated cell death is FasL, we tested the cytotoxic activity of concentrated supernatant harvested from Neuro2A cells transfected with the murine FasL complementary DNA. These experiments confirmed that the sensitivity of HT29 cells to Fas-mediated cytotoxicity was greatly enhanced by treatment of cells with either cisplatin or IFN ␥ (Fig. 6) . The cytotoxic activity of both clone CH11 antibody and FasL-transfected Neuro2A cell supernatant was prevented by the antagonistic anti-Fas ZB4 monoclonal antibody, which indicates the Fas specificity of the cytotoxic process (Fig.  6 ). Taken together, these data show that cisplatin treatment increases the expression of a functional Fas on the surface of tumor cells and enhances Fas-mediated cytotoxicity.
Studies (14, 16) have demonstrated the ability of FasLexpressing effector cells to kill Fas-bearing target cells in a granule-independent manner. To determine whether the enhancement of Fas receptor expression on cisplatin-treated HT29 cells could increase their sensitivity to Fas-dependent, cellmediated cytotoxicity, we isolated allogeneic PBLs from healthy donors and tested their non-major histocompatibility complexrestricted cytolytic activity against HT29 cells in a 16-hour 51 Cr release assay. In all of these experiments, the human leukemia cell lines K562 and HL60 were used as positive and negative controls, respectively (data not shown). PBLs were slightly cytolytic toward untreated HT29 cells (Fig. 7, A) . Their cytotoxic effect was increased by about fourfold when target HT29 cells were treated for 4 hours with 10 M cisplatin. Under these conditions, a 25:1 effector-to-target ratio using untreated PBLs as effector cells and cisplatin-treated HT29 cells as target cells gave similar 51 Cr release compared with a 100:1 effector-totarget ratio using the same untreated PBLs as effector cells and untreated HT29 cells as target cells (Fig. 7, A and B) . Preincubation of target HT29 cells for 1 hour in the presence of 2 g/mL Fas-blocking ZB4 antibody, which remained in the culture medium during exposure to PBLs, did not modify the cytolytic activity of PBLs toward untreated cells, but it completely sup- pressed the increased cytolytic activity of PBLs toward cisplatin-treated HT29 cells (Fig. 7, A and B) . No protective effect was observed when an isotype-matched antibody was used as control (data not shown). These results indicate that cisplatin treatment of tumor cells increases the Fas-mediated cytotoxic activity of PBLs toward these cells.
The increased Fas-dependent cytolytic activity of PBLs toward cisplatin-treated compared with untreated HT29 cells could have been the consequence of an increased expression of FasL on PBLs incubated in the presence of cisplatin-treated HT29 cells. By use of a reverse transcription-polymerase chain reaction, FasL gene expression was detected in freshly isolated PBLs. Fas messenger RNA was slightly increased when PBLs had been incubated in the presence of either untreated or cisplatin-treated HT29 cells (data not shown). FasL expression on the surface of PBLs was evaluated by flow cytometry using the biotinylated IgG anti-human FasL clone NOK-1. Freshly isolated PBLs expressed FasL (Fig. 8, A) . When PBLs had been incubated in the presence of either untreated or cisplatin-treated HT29 cells, the expression of FasL on the surface of PBLs was only slightly increased, independently of the target cell treatment (Fig. 8, B and C) . Moreover, soluble FasL remained undetectable in the supernatants of these cocultures, as determined by use of a 24-hour cytotoxic assay on Jurkat cells (25) (data not shown). These results indicate that increased Fas-dependent cytotoxicity of PBLs toward cisplatin-treated HT29 cells is not the consequence of increased FasL synthesis by the PBLs.
Discussion
A loss of Fas expression or function has been described in malignant cells relative to normal cells of several tissues, including breast (26) , colon (9), testis (27) , liver (28, 29) , and hematopoietic cells (30) . The loss of expression of Fas suggests that cancer cells could escape the normal induction of apoptosis that occurs in these tissues (9, 26) . The demonstration that sen- Fig. 3 . Expression and regulation of Fas gene expression in untreated (NT) and cisplatin (CDDP)-treated or interferon ␥ (IFN-␥)-treated HT29 cells as described in Fig. 2. A) Northern blot analysis of Fas messenger RNA (mRNA) level. The human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) complementary DNA probe was used as an internal control. B) Transcription rate as measured by the in vitro nuclear runon assay. In panels A and B, the ratio of Fas to GAPDH mRNA was calculated by densitometric analysis and is expressed in arbitrary units. Both panels show one experiment representative of three different experiments. Fig. 4 . Post-transcriptional regulation of Fas gene expression, as determined by northern blot hybridization assays in untreated (NT) and cisplatin (CDDP)-treated or interferon ␥ (IFN-␥)-treated HT29 cells (described in Fig. 2 ) in the absence and in the presence of 5 g/mL dactinomycin (i.e., actinomycin-D). One experiment representative of three different experiments is shown. GAPDH ‫ס‬ glyceraldehyde-3-phosphate dehydrogenase. sitivity to Fas-mediated apoptosis could be restored in these cells by treatment with IFN ␥ (9,26) indicated that the expression of Fas and the Fas pathway had been modulated during tumor progression but that the components of the Fas pathway had not been lost through mutation events. Our study demonstrates that, like IFN ␥, cytotoxic drugs can enhance the sensitivity of tumor cells to Fas-mediated apoptosis.
Cytotoxic drugs and IFN ␥ increase the expression of Fas receptor on the plasma membrane of HT29 tumor cells by increasing both Fas gene transcription and messenger RNA stability. Cisplatin was shown recently to enhance also the expression of Fas receptor on cultured human keratinocytes (31) . The cisplatin-induced overexpression of Fas receptor is independent of the p53 status, since it was observed in p53-mutated HT29 and U937 cells as well as in p53 wild-type HCT116 and HCT8R cells. Enhancement of Fas gene transcription and subsequent Fas receptor expression could be only part of the mechanism by which cisplatin sensitizes tumor cells to Fas-mediated cell death. Hence, although target cells expressing a higher level of Fas receptor were shown to be more sensitive to natural killer cell cytolytic activity (32) , the spontaneous expression of Fas receptor on tumor cells was not predictive of the cell-killing efficiency of anti-Fas antibodies (33) . Moreover, IFN ␥ was previously shown to induce Fas sensitivity in some tumor cell lines without changing the level of Fas protein (34) . In any event, cisplatin treatment of tumor cells increases the sensitivity of these cells to agonistic anti-Fas antibodies, to soluble FasL, and to allogeneic PBL-mediated cytotoxicity. Furthermore, each of these effects was blocked by co-treatment of the cells with antagonistic antiFas antibody. Two reasons could account for the low cytotoxicity of allogeneic PBLs compared with FasL-containing supernatant on cisplatin-treated cells. First, PBLs could express fewer FasL molecules. Second, the Fas-dependent pathway is only part of the mechanisms by which immune cells can kill target cells (35) .
We have recently shown (36) that the cell death pathways triggered in human leukemia cells by either a DNA-damaging agent or an agonistic anti-Fas antibody involve a protease inhibited by the tetrapeptide Ac-DEVD-CHO, suggesting that a combination of these death inducers will converge to a final common pathway. Several recent reports (13) (14) (15) 32, 37) have emphasized the complex and ambiguous role of the Fas/FasL system in the clearance of tumor cells by either immune cells or cytotoxic drugs. First, the Fas-mediated pathway was involved in the cytotoxicity of activated T cells and natural killer cells, in addition to the perforin/granzyme-dependent pathway. The Fas system was shown to possess a tumor-suppressor function in a T-cell-deficient mouse model (38) . Second, it was shown that both colon cancer cells and melanoma cells could express functional FasL and induce apoptosis of activated T cells, a mechanism that may contribute to the immune privilege of tumor cells (21, 22) . Third, apoptosis of human CEM and Jurkat leukemia cells induced by the cytotoxic drugs doxorubicin and methotrexate was suggested to be mediated via the Fas/FasL system (6). The additional information provided by our study is that DNAdamaging agents can up-regulate (i.e., increase) Fas receptor expression on tumor cells, thereby increasing the Fas-dependent, non-major histocompatibility complex-restricted cytotoxic activity of PBLs toward these cells. When considered together, these data indicate that tumor cell outcome (i.e., death or sur- Possible therapeutic use of the agonistic anti-Fas antibodies was first proposed for the treatment of Epstein-Barr virusinduced lymphoproliferative diseases in immunocompromised individuals (39) , in patients with human leukemia virus type 1-associated malignant disorders (40) , and in patients with acquired immunodeficiency syndrome (41) . However, intraperitoneal administration of an anti-Fas antibody in mice induced lethal liver damage within 6 hours (42). It is interesting that FasL did not induce histopathologic abnormalities in the liver when it was applied intraperitoneally at cytotoxic doses; however, intravenous administration of FasL induced lethal hemorrhages and hepatocyte apoptosis (23) . Thus, locally applied FasL, in combination with cytotoxic drugs, may represent a candidate for local (i.e., intrathecal or intratumoral) tumor treatment.
Our study provides the first evidence that chemotherapeutic drugs, whose direct cytotoxic effects are well known, also exhibit an indirect cytotoxic activity by preparing the tumor cells to be eliminated by the immune system using a Fas-dependent pathway. The combination of cytotoxic drugs with anti-Fas antibodies was shown to overcome drug resistance of human tumor cell lines, and its efficacy was significantly augmented by pretreatment with IFN ␥ (43). The combination of FasL with cytotoxic drugs that increase tumor cell sensitivity to Fas-mediated cell death and/or with biologic response modifiers that activate the natural killer cells and T lymphocytes for in vivo secretion of IFN ␥ constitutes new potential strategies that could improve the efficacy of cancer treatment. 
